-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDISIN US81750R1023-
SERES THERAPEUTICS INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 1S9
-
SERES THERAPEUTICS INCBörse Börse FrankfurtEURSymbol 1S9
-
SERES THERAPEUTICS INCBörse Börse StuttgartEURSymbol 1S9
-
SERES THERAPEUTICS INCBörse Börse BerlinEURSymbol 1S9
-
ISIN US81750R1023 WKN: A14VXXUSDSymbol MCRB
-
EUR
-
ISIN US81750R1023
WKN A14VXX
Symbol MCRB
Währung
USD
Firmenname
Seres Therapeutics, Inc
Marktkapitalisierung
2.042.946.144 (+- 12%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.294.892.288 oder 1.791.000.000
Mitarbeiter
270 (+- 60%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
108 oder 431 Mitarbeiter
EBITDA -69.997.000
PEGRatio -0.11
Buchwert 2.062
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 33 USD -4,43%
Entdecke die 6 ETFs in denen Seres Therapeutics, Inc am höchsten gewichtet ist Insgesamt in 7 ETFs enthalten
Dir gefallen die Informationen zu Seres Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Seres Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Seres Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Seres Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
33 News & Informationen zur Seres Therapeutics Inc Aktie
Cathie Wood’s ARK Invest Sells Over 840,000 Shares of Seres Therapeutics – 24
One of Cathie Wood's ARK Invest exchange-traded funds sold over 840,000 shares of Seres Therapeutics on August 30.
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 30, 2021.
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
/PRNewswire/ — Laronde, the company pioneering Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins…
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 27, 2021.
Cathie Wood’s ARK Invest Sells Over 300,000 Shares of Iovance Bio – 24
One of Cathie Wood's ARK Invest funds sold over 300,000 shares of cancer-focused biopharma startup Iovance Bio on August 26.
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 26, 2021.
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 24, 2021.
Global Microbiome Market Marching Towards The Mainstream
DUBLIN, Aug. 24, 2021 /PRNewswire/ — The
Global Microbiome Market Marching Towards the Mainstream
/PRNewswire/ — The
Cathie Wood’s ARK Invest Sells Nearly $30 Million Worth of Alphabet – 24
A couple of Cathie Wood's ARK Invest exchange-traded funds sold over 10,000 shares of Alphabet on August 23.
Cathie Wood’s ARK Invest Sells Over 40,000 Shares of Baidu – 24
One of Cathie Wood's Ark Invest funds sold over 40,000 shares of Baidu on August 18.
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Johnson & Johnson (NYSE: JNJ) Laboratory Corporation of America Holdings (NYSE: LH) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) NanoVibronix, Inc. (NASDAQ: NAOV) (announced intention to enter over-
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 16, 2021.
Fairmount Funds Management LLC Buys Instil Bio Inc, Zogenix Inc, Insmed Inc, Sells Mirati Therapeutics Inc, Seres Therapeutics Inc, Trillium Therapeutics Inc
GuruFocus Article or News written by insider and the topic is about:
Cathie Wood’s ARK Invest Sells Over 280,000 Shares of Twitter – 24
One of Cathie Wood's ARK Invest funds sold over 280,000 shares of Twitter on August 11.
Cathie Wood’s ARK Invest Dumps Nearly $39 Million Worth of Netflix Stock – 24
One of Cathie Wood's ARK Invest funds sold over 75,000 shares of Netflix on August 10.
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest sells for August 10, 2021.
Cathie Wood’s ARK Invest Sells for 8
Here's a look at the ARK Invest buys for August 5, 2021.
Cathie Wood’s ARK Invest Sells Over 60,000 Shares of Square – 24
One of Cathie Wood's Ark Invest exchange-traded funds sold over 60,000 shares of Square on August 4.
Seres Therapeutics To Present At Canaccord Genuity 41st Annual Growth Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results – Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2021 Earnings Conference Call August 03, 2021, 08:30 AM ET Company Participants Carlo Tanzi – IR Eric Shaff – President and CEO David Arkowitz -…
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis …
Is Immunocore Holdings plc (IMCR) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession…
Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.16% to 34,853.89 while the NASDAQ rose 0.38% to 14,687.85. The S&P also rose, gaining 0.20% to …
Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge
Midway through trading Thursday, the Dow traded down 0.08% to 34,768.64 while the NASDAQ rose 0.10% to 14,646.39. The S&P also fell, dropping …
Why Seres Therapeutics Stock Is Crashing Today
The company reported disappointing results from a phase 2b clinical study.
Seres Therapeutics : to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline… | July 22, 2021
Seres Therapeutics Announces Topline Results For SER-287 Phase 2b Study In Mild-to-Moderate Ulcerative Colitis
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
(NASDAQ:MCRB)Seres Therapeutics inks SER-109 commercialization agreement in $525M deal
Seres Therapeutics (MCRB)has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109 for recurrent Clostridioides difficile infection ((CDI)),…
Intellia Shares Soar on Positive Test Results
GuruFocus Article or News written by Barry Cohen and the topic is about: Merck, Sanofi, Gilead and others stand to benefit from clinical trials
Flagship Pioneering Unveils Inzen Therapeutics
/PRNewswire/ — Flagship Pioneering, a life science platforms company, today announced the unveiling of Inzen Therapeutics. Flagship created Inzen in 2017 to…
Venture Capital Access Online